Streetbeat News

Earnings

FUBO

FuboTV Inc reported Q2 FY23 sales growth of 41% YoY to $312.7 million, beating the consensus of $301.9 million. Adjusted EPS loss of $(0.12) beat the consensus loss of $(0.23). The company ended the quarter with $299.7 million of cash and equivalents. FuboTV sees Q3 North America revenue of $272.5 million-$277.5 million and Rest of the World revenue of $7.2 million-$8.2 million. FUBO shares were up 9.3% at $3.50 at last check Friday.

Portfolio Pulse from Anusuya Lahiri

August 04, 2023 | 3:31 pm

ASRT

INVO

MESO

MF

TUP

USM

US stocks rose following the release of jobs data, with the Dow, NASDAQ, and S&P 500 all seeing gains. The US economy added 187,000 jobs in July, missing market estimates of 200,000. Missfresh Limited (MF), United States Cellular Corporation (USM), and Tupperware Brands Corporation (TUP) saw significant stock increases, while Mesoblast Limited (MESO), Assertio Holdings, Inc. (ASRT), and INVO Bioscience, Inc. (INVO) saw stock decreases.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 3:30 pm

TDS

USM

Telephone And Data Systems, Inc. (TDS) and United States Cellular Corporation (USM) are exploring strategic alternatives, causing TDS stock to jump over 28%. TDS owns 83% of UScellular. Both companies reported Q2 FY23 revenues below consensus, with TDS reporting a loss of $(0.17) per share and UScellular reporting earnings of $0.05 per share. TDS sees FY23 UScellular sales of $3.025 billion-$3.075 billion.

Portfolio Pulse from Nabaparna Bhattacharya

August 04, 2023 | 3:30 pm

USM

UScellular reported worse-than-expected Q2 financial results, yet its shares are trading higher.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 3:29 pm

DBRG

DigitalBridge Gr (NYSE:DBRG) reported Q2 GAAP EPS of $(0.14), beating the estimate of $(0.25) by 44%. The company also reported quarterly sales of $424.93M, surpassing the estimate of $298.95M by 42.14%. Both earnings and sales have increased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 3:29 pm

AMRX

Amneal Pharmaceuticals Inc (AMRX) reported Q2 revenue of $599 million, a 7% Y/Y increase, beating the consensus of $562.49 million. The growth was driven by generics' growth, new product launches, and expansion across AvKARE. The company raised its FY23 revenue guidance to $2.30-$2.40 billion, up from the prior guidance of $2.25-$2.35 billion. AMRX shares are up 9.53% at $3.68.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 3:29 pm

SYK

Stryker Corporation (NYSE:SYK) reported Q2 sales of $5 billion, up 11.2% Y/Y, beating the consensus of $4.83 billion. Organic net sales increased 11.9% in the quarter. Adjusted EPS came in at $2.54, beating the consensus of $2.38. Stryker predicts 2023 organic net sales growth of 9.5%-10.5%, up from the previous range of 8%-9%. The company now expects 2023 adjusted EPS of $10.25-$10.45 versus prior guidance of $10.05-$10.25. SYK shares are up 3.04% at $284 premarket on the last check Friday.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 3:29 pm

NKLA

Nikola Corp announced a sudden change in CEO and reported mixed results for the second quarter, leading to a drop in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 3:29 pm

ASRT

Assertio Therapeutics reported its Q2 financial results and withdrew its 2023 financial outlook due to the recent approval of a generic indomethacin suppository by the US FDA. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 3:28 pm

AMGN

Amgen Inc has reported Q2 FY23 sales of $6.99 billion, a 7% increase Y/Y, beating the consensus of $6.63 billion. The company also released positive topline data from tarlatamab Phase 2 DeLLphi-301 study in relapsed or refractory small-cell lung cancer and Lumakras Phase 3 CodeBreaK 300 trial in colorectal cancer. However, Amgen announced discontinuing further enrollment in the study of Lumakras combined with a PD-1 inhibitor in KRAS G12C mutated NSCLC. The company has raised its FY23 revenue outlook to $26.6-$27.4 billion from the previous range of $26.2-$27.3 billion.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 3:28 pm